Aringer, M 
; Burkhardt, H ; Burmester, GR ; Fischer-Betz, R ; Fleck, M ; Graninger, W ; Hiepe, F ; Jacobi, AM ; Kötter, I ; Lakomek, HJ ; Lorenz, HM ; Manger, B ; Schett, G ; Schmidt, RE ; Schneider, M ; Schulze-Koops, H ; Smolen, JS ; Specker, C ; Stoll, T ; Strangfeld, A ; Tony, HP ; Villiger, PM ; Voll, R ; Witte, T ; Dörner, T
; Burkhardt, H ; Burmester, GR ; Fischer-Betz, R ; Fleck, M ; Graninger, W ; Hiepe, F ; Jacobi, AM ; Kötter, I ; Lakomek, HJ ; Lorenz, HM ; Manger, B ; Schett, G ; Schmidt, RE ; Schneider, M ; Schulze-Koops, H ; Smolen, JS ; Specker, C ; Stoll, T ; Strangfeld, A ; Tony, HP ; Villiger, PM ; Voll, R ; Witte, T ; Dörner, T 
Zusammenfassung
Systemic lupus erythematosus (SLE) can be a severe and potentially life-threatening disease that often represents a therapeutic challenge because of its heterogeneous organ manifestations. Only glucocorticoids, chloroquine and hydroxychloroquine, azathioprine, cyclophosphamide and very recently belimumab have been approved for SLE therapy in Germany, Austria and Switzerland. Dependence on ...
Nur für Besitzer und Autoren: Kontrollseite des Eintrags
Altmetric